Navigation Links
Sinovac Reports Third Quarter 2008 Unaudited Financial Results
Date:11/18/2008

would be retroactive to January 1, 2008, according to the newly enacted Enterprises Income Tax Law. Assuming HNTE is received, the impact on the results of operations for the nine months ended September 30, 2008 would include a $1,667,726 decrease in the provision of the current income tax with a corresponding reduction in the income tax liability and a $905,687 increase in deferred income tax expense with an offset to deferred income tax assets. The change of rate will be recorded in the period that changes occur.

As of September 30, 2008, Sinovac's cash and cash equivalents totaled $20.5 million, compared to $18.8 million as of June 30, 2008. The 9% increase in cash and cash equivalents compared to the second quarter of 2008 was primarily attributable to improved accounts receivables collection.

Nine Months Ended September 30, 2008

For the nine months ended September 30, 2008, sales reached $34.1 million, compared to $24.3 million for the same period of 2007, representing a 40% growth rate.

During the nine months ended September 30, 2008, Sinovac sold 5.3 million doses of Healive(R), compared to 4.1 million doses for the same period of 2007. The Company sold 234,000 doses of Bilive(R) during the 2008 period, compared to nil doses in the prior year period. As mentioned previously, the year- over-year change in sales was in line with the Company's sales and marketing strategy. For the first nine months of 2008, Healive, Anflu, and Bilive as a percentage of sales represented 91%, 5% and 4%, respectively.

Gross profit for nine months ended September 30, 2008 was $28.8 million, with a gross margin of 84.4%, compared to $20.7 million and 85.2% for the same period of 2007. The change in gross margin as a percentage of sales was primarily attributable to the product sales mix during the 2008 period.

Total operating expenses for the nine months ended September 30,
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Sinovac Named to Deloitte Technology Fast 50 China
2. Sinovac to Participate in Two Upcoming Investor Conferences
3. Sinovacs Credit Rating Upgraded to AAZ, Second Highest Rating
4. Sinovac Biotech Holds 2007 Annual General Meeting
5. Sinovac to Present at the 2008 UBS Global Life Sciences Conference
6. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
7. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
8. Sinovac Adjourns Annual General Meeting
9. Sinovac to Present at the Susquehanna Financial Groups Second Annual Beijing Management Summit Conference
10. Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
11. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014 /PRNewswire/ ... company focused on gynecologic disease, announced today that ... with investors including Oracle Investment Management, Jack ... Vermillion directors. Total proceeds were $10.5 million, before ... working capital and general corporate purposes. ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn ... biotechnology company, Syngenta, are in the process of being ... The consolidated case is In Re: Syngenta AG MIR ... District Court for the District of Kansas. , Management ... been handed over to U.S. District Judge John W. ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 On ... law H.R. 83, the Omnibus and Continuing Resolution ... time, made hydrocephalus a condition eligible to receive ... (CDMRP) administered by the Department of Defense (DoD). ... its allies on Capitol Hill, is celebrating this ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. George ... Society for Reproductive Medicine (ASRM), a leading professional organization ... In his new role as treasurer, Dr. Hill ... will have a voice in furthering the mission of ... since 1984 when he joined while conducting fellowship training ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... , , ST. LOUIS, ... SIAL ), and MIP Technologies AB announced today the launch of ... extraction of non-steroidal anti-inflammatory drugs (NSAIDs). , ... portfolio because it targets a critical area of public concern - ...
... Comprehensive tutorials on ... these invaluable resources. , ... WA (PRWEB) July 16, 2009 -- OpenHelix today announced the availability of new tutorial ... dbGaP resource is a database of genotypes and phenotypes with extensive variation ...
... , , , SEATTLE, ... its series A financing round. The infusion of capital assures the company of ... variety of cellulosic materials (such as algae, plants and food waste) into a ... part of the agreement, the lead investor has joined the board of Blue ...
Cached Biology Technology:Supelco(R) and MIP Technologies Launch New SPE Product for the Selective Extraction of NSAIDs From Environmental Water 2Supelco(R) and MIP Technologies Launch New SPE Product for the Selective Extraction of NSAIDs From Environmental Water 3New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix 2New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix 3
(Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
(Date:12/3/2014)... , Dec. 2, 2014   Marvin ... deployed, innovative test solutions for military, aerospace, and ... version of its successful TS-900 PXI semiconductor ... and features of high-end systems to customers at ... value compared to traditional ATE. ...
(Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... are obese, have type 2 diabetes or a family history ... pregnancies because of a study at Washington University School of ... mice, suggests that Metformin, the most commonly prescribed anti-diabetes drug, ... We found that embryos of insulin-resistant mice also ...
... and IC-MedTech Inc. has yielded an innovative liquid crystal technology ... effectively manage cancer and other diseases. The American Cancer Society ... be diagnosed this year. This crisis has caused the National ... death due to cancer by the year 2015. ...
... Sept. 6, 2007 Seattle Childrens Hospital will receive ... a new five-year, eleven-part grant awarded by the National ... $23.7 million grant will support the Northwest Genome Engineering ... Childrens Hospital Research Institute in partnership with the University ...
Cached Biology News:Drug could improve pregnancy outcomes in wider range of women with insulin resistance 2Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases 2Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases 3Seattle Children's Hospital leads $23.7 million NIH grant to study gene repair 2Seattle Children's Hospital leads $23.7 million NIH grant to study gene repair 3
... AVOID FREEZE/THAW CYCLES. An assay kit ... by Western blotting. PARP is an enzyme ... During apoptosis, PARP is cleaved by caspase-3. ... kDa to 85 kDa is a hallmark ...
... handy dispensers save space and ... hats, and other garb. They ... bins for small parts used ... Clear acrylic. Open-slot design for ...
... is expressed in g per ml and is ... pH 6.8, of a 1 mg per ml ... concentration to agglutinate a 2% suspension of human ... at 25 C. Preparation Note: Affinity ...
... dispensers save space and organize gloves, ... garb. They are the perfect benchtop ... in labs, processing and manufacturing. Clear ... the particles they attract. Open-slot design ...
Biology Products: